Drugs to prevent hpv infection
US-2015297602-A1 · Oct 22, 2015 · US
US10458991B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10458991-B2 |
| Application number | US-201615752870-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 12, 2016 |
| Priority date | Aug 14, 2015 |
| Publication date | Oct 29, 2019 |
| Grant date | Oct 29, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
In an example of a method for simultaneously fixing and staining cells, the cells are initially incubated in a solution including a Ln(III)Zn16(HA ligand)16 metallacrown complex, wherein the HA ligand is a hydroximate ligand. The incubating cells are exposed to ultraviolet (UV) light. The cells are allowed to continue to incubate in the solution after UV light exposure.
Opening claim text (preview).
The invention claimed is: 1. A method for simultaneously fixing and staining cells, the method comprising: initially incubating the cells in a solution including a Ln(III)Zn 16 (HA ligand) 16 metallacrown complex, wherein the HA ligand is a hydroximate ligand; exposing the incubating cells to ultraviolet (UV) light; and continuing to incubate the cells in the solution after UV light exposure. 2. The method of claim 1 wherein: the solution includes the Ln(III)Zn 16 (HA ligand) 16 metallacrown complex in a medium; and a concentration of the Ln(III)Zn 16 (HA ligand) 16 metallacrown complex in the solution ranges from about 90 μM to about 400 μM. 3. The method of claim 1 , further comprising culturing the cells prior to incubating the cells in the solution. 4. The method of claim 1 , wherein: initially incubating the cells is accomplished for a time (T1) ranging from about 10 minutes to about 3 hours; exposing the incubating cells to UV light is accomplished for a time (T2) ranging from about 5 minutes to about 10 minutes; and continuing to incubate the cells is accomplished for a time (T3) ranging from about 1 hour to about 2 hours. 5. The method as defined in claim 4 , further comprising exposing the incubating cells to additional UV light for a time (T4) ranging from about 1 minute to about 5 minutes. 6. The method of claim 1 , wherein the HA ligand of the Ln(III)Zn 16 (HA ligand) 16 metallacrown complex is selected from the group consisting of pyrazinehydroximate, quinoxalinehydroximate, quinaldinehydroximate, and combinations thereof. 7. The method as defined in claim 6 wherein: the Ln(III)Zn 16 (HA ligand) 16 metallacrown complex is one of: [Ln(III)Zn 16 (pyrazinehydroximate) 16 (pyridine) 8 ] counter ion; [Ln(III)Zn 16 (quinoxalinehydroximate) 16 (pyridine) 8 ] counter ion; or [Ln(III)Zn 16 (quinaldinehydroximate) 16 (pyridine) 8 ] counter ion; wherein the Ln(M) is selected from the group consisting of Y 3+ , La 3+ , Ce 3+ , Pr 3+ , Nd 3+ , Pm 3+ , Sm 3+ , Eu 3+ , Gd 3+ , Tb 3+ , Dy 3+ , Ho 3+ , Er 3+ , Tm 3+ , Yb 3+ , and Lu 3+ ; and wherein the counter ion is selected from the group consisting of a triflate, a mesylate, a besylate, a camsylate, an edisylate, an estolate, an esylate, a napsylate, a tosylate, a fluoride, a chloride, a bromide, an iodide, a nitrate, a sulfate, a carbonate, an acetate, a phosphate, and a sulfonate. 8. The method as defined in claim 6 wherein: the Ln(III)Zn 16 (HA ligand) 16 metallacrown complex includes a mixture of metallacrown complexes; each species in the metallacrown mixture is [Ln(III)Zn 16 (pyrazinehydroximate) x (quinoxalinehydroximate) y (pyridine) 8 ] counter ion, wherein x+y=16; wherein the Ln(M) is selected from the group consisting of Y 3+ , La 3+ , Ce 3+ , Pr 3+ , Nd 3+ , Pm 3+ , Sm 3+ , Eu 3+ , Gd 3+ , Tb 3+ , Dy 3+ , Ho 3+ , Er 3+ , Tm 3+ , Yb 3+ , and Lu 3+ ; and wherein the counter ion is selected from the group consisting of a triflate, a mesylate, a besylate, a camsylate, an edisylate, an estolate, an esylate, a napsylate, a tosylate, a fluoride, a chloride, a bromide, an iodide, a nitrate, a sulfate, a carbonate, an acetate, a phosphate, and a sulfonate. 9. The method of claim 8 , wherein x ranges from 8 to 13 and y ranges from 3 to 8. 10. The method of claim 1 , wherein the medium is a serum-supplemented medium. 11. The method of claim 1 , wherein the UV light is UV-A light. 12. The method of claim 1 , wherein: UV light exposure induces death of at least some of the cells; and after continuing to incubate the cells, the Ln(III)Zn 16 (HA ligand) 16 metallacrown complex is located in nuclei and cytoplasm of least some dead cells.
with non-fluorescent dye label · CPC title
Zinc compounds · CPC title
Fluorescence microscopy (fluorescence microscopes per se G02B21/0076 and G02B21/16) · CPC title
Stain compositions · CPC title
Fixative compositions · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.